Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaCPLFY 97 EV-to-EBIT is 17.44 as of Jul. 26, 2026, which is 17% below its 10-year median of 21.10. GuruFocus rates CPLFY with a GF Score™ of 97/100. The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Cipla ranks worse than 65.22% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cipla's Enterprise Value is $8,814.68 Mil.
Cipla's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $505.43 Mil. Therefore, Cipla's EV-to-EBIT for today is 17.44.
The historical rank and industry rank for Cipla's EV-to-EBIT or its related term are showing as below:
CPLFY'
s EV-to-EBIT Range Over the Past 10 Years
Min: 12.52 Med: 21.1 Max: 41.3
Current: 22.79
During the past 13 years, the highest EV-to-EBIT of Cipla was 41.30. The lowest was 12.52. And the median was 21.10.
CPLFY's EV-to-EBIT is ranked worse than 65.22% of 690
companies
in the Drug Manufacturers industry
Industry Median: 15.42
vs CPLFY: 22.79
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cipla's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Cipla's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $505.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla EV-to-EBIT Related Terms
Cipla EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cipla's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cipla's EV-to-EBIT falls into.
Cipla's current Enterprise Value is $8,814.68 Mil.
Cipla's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $505.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (CPLFY) has a EV-to-EBIT of 17.44 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cipla and its competitors. This is 17% below median its historical median of 21.10. Over the past decade, Cipla's EV-to-EBIT has ranged from 12.52 to 41.30. According to the industry distribution chart, Cipla ranks #450 out of 690 companies in the Drug Manufacturers industry, placing it in the top 65.2%.
Is Cipla's EV-to-EBIT too high?
Cipla's current EV-to-EBIT of 17.44 is 17% below median its 10-year median of 21.10. Over the past 10 years, this metric has ranged from a low of 12.52 to a high of 41.30. The Drug Manufacturers industry median EV-to-EBIT is 15.42. Cipla's value of 17.44 is 13.1% above this industry median. Based on the distribution chart, Cipla ranks #450 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #450 out of 690 companies for EV-to-EBIT. This places Cipla in the lower half of its industry. The industry median EV-to-EBIT is 15.42. Cipla's value of 17.44 is 13.1% above this benchmark. Historically, Cipla's own EV-to-EBIT has ranged from 12.52 to 41.30 over the past decade. While the company's 10-year median is 21.10 vs. the industry median of 15.42, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.42, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current EV-to-EBIT of 17.44 is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current EV-to-EBIT is 17.44, which is 17% below median its own 10-year median of 21.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current EV-to-EBIT of 17.44. The current EV-to-EBIT is 17.44, which is 17% below median its 10-year median of 21.10 and 13.1% above the Drug Manufacturers industry median of 15.42. Cipla's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cipla (CPLFY), the current EV-to-EBIT is 17.44 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 
